Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Make Breakthrough in Understanding Rare Blood Cancer

December 9, 2014 8:51 am | by University of Southampton | News | Comments

A breakthrough in understanding of a rare form of blood cancer could lead to significant improvements in treatment for patients. Read more...                    


AbbVie Announces Phase 2 Results for AML Treatment

December 8, 2014 3:07 pm | News | Comments

AbbVie presented new results from a Phase 2 study of a treatment for AML at the American Society of Hematology's 56th Annual Meeting. Read more...                   


Bad Data Adds Another Problem to Ebola Outbreak

December 8, 2014 2:50 pm | by Maria Cheng and Sarah Dilorenzo - Associated Press | News | Comments

Having accurate numbers about the Ebola outbreak is essential not only to provide a realistic picture of the epidemic, but to determine effective control strategies. Read more...            


A Pill to Shed Fat?

December 8, 2014 2:36 pm | by B.D. Colen, Harvard University | News | Comments

Researchers created a system using human stem cells to screen for compounds that have the potential to turn white fat cells into brown fat cells. Read more...             


Tasigna Wins Over Gleevec in Ph+CML Patients

December 8, 2014 1:45 pm | News | Comments

Six-year results from Novartis' randomized Phase 3 study continue to demonstrate the superiority of Tasigna compared to Glivec. Read more...                   


New Agent Shrinks Small Cell Lung Tumors in Pre-Clinical Testing

December 8, 2014 1:20 pm | News | Comments

Researchers found that a new agent can disable the basic part of a tumor cell's survival mechanism. Read more...                         


New Immunotherapy Breakthrough Discovered

December 8, 2014 1:06 pm | by Robert Levy, Harvard Medical School | News | Comments

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma into complete or partial remission. Read more...                     


FDA Approves Amgen's Hypercalcemia Drug

December 8, 2014 12:53 pm | News | Comments

The FDA approved Amgen's drug that treats hypercalcemia. Read more...                                


Pfizer Expands Rare Disease Research with Gene Therapy Platform

December 8, 2014 12:34 pm | News | Comments

Pfizer announced two strategic decisions to expand the company’s rare disease research and development activities. Read more...                       


Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 12:27 pm | by Tom Murphy - AP Business Writer | News | Comments

Merck will spend $8.4 billion to buy Cubist Pharmaceuticals. Read more...                                


Journal Watch: Tamoxifen in the News Again

December 8, 2014 11:57 am | by Drug Discovery & Development Staff | Articles | Comments

Tamoxifen, the leading estrogen blocker, has done so well by hormone receptor-positive breast cancer patients that the American Society for Clinical Oncology (ASCO) changed its guidelines this year, advising certain patients to take the drug for ten years instead of five. Read more...


BioDelivery Sciences: Phase 3 Trial of Diabetic Neuropathy Topical Gel

December 8, 2014 10:52 am | News | Comments

BioDelivery Sciences International, Inc. announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). Read more...


Norovirus Sickens 200 People on New Zealand Cruise

December 8, 2014 10:41 am | by Associated Press | News | Comments

Health authorities in New Zealand said that about 200 passengers on a cruise ship have been sickened by an outbreak of norovirus. Read more...                                                    


Breakthrough in Fibrosis Research

December 8, 2014 10:33 am | by University of Bath, UK | News | Comments

Researchers from the Departments of Pharmacy & Pharmacology and Biology & Biochemistry have made an important discovery that might lead to novel therapies to combat chronic fibrotic diseases. Read more...                          


Amgen, Onyx: Phase 3 Study Results in Myeloma Trial

December 8, 2014 10:26 am | News | Comments

Amgen and its subsidiary Onyx results of the Phase 3 ASPIRE trial, which evaluated Kyprolis (carfilzomib) for Injection plus Revlimid (lenalidomide) and dexamethasone (KRd) compared with Revlimid and dexamethasone (Rd) in patients with relapsed multiple myeloma. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.